Adaptive designs for multi-armed clinical trials have become increasingly popular recently because of their potential to shorten development times and to increase patient response. However, developing response-adaptive designs that offer patient-benefit while ensuring the resulting trial provides a statistically rigorous and unbiased comparison of the different treatments included is highly challenging. In this paper, the theory of is used to define near optimal adaptive designs in the context of a clinical trial with a normally distributed endpoint with known variance. We report the operating characteristics (type I error, power, bias) and patient-benefit of these approaches and alternative designs using simulation studies based on an ongoing trial. These results are then compared to those recently published in the context of Bernoulli endpoints. Many limitations and advantages are similar in both cases but there are also important differences, specially with respect to type I error control. This paper proposes a simulation-based testing procedure to correct for the observed type I error inflation that bandit-based and adaptive rules can induce.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856359PMC
http://dx.doi.org/10.1080/02664763.2017.1342780DOI Listing

Publication Analysis

Top Keywords

type error
12
adaptive designs
8
designs
5
bayesian adaptive
4
adaptive bandit-based
4
bandit-based designs
4
designs gittins
4
gittins multi-armed
4
multi-armed trials
4
trials distributed
4

Similar Publications

Background: The well-accepted statistical efficacy inference approach for Alzheimer's disease (AD) clinical trials compares the absolute difference in change from baseline at the last study visit using MMRM (henceforth referred to as MMRM-Last-Visit). Recent AD clinical trials have shown that treatment effects may be manifested prior to 18 months. The objective is to evaluate models estimating an overall treatment effect across all post-baseline visits that may characterize disease modifying effects in contemporary early AD clinical trials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Anavex Life Sciences, New York, NY, USA.

Background: In AD trials, the treatment effect is typically evaluated by estimating the absolute difference in change from baseline to the end-of-study visit (e.g., 18 months) between treatment arms using the MMRM model.

View Article and Find Full Text PDF

Technology and Dementia Preconference.

Alzheimers Dement

December 2024

Cumulus Neuroscience, Dublin, Ireland.

Background: Current tools for Alzheimer's disease screening and staging used in clinical research (e.g. ACE-3, ADAS-Cog) require substantial face-to-face time with trained professionals, and may be affected by subjectivity, "white coat syndrome" and other biases.

View Article and Find Full Text PDF

Background: Walking is a key facilitator of healthy ageing and may reduce risk of cognitive decline in older adults. To develop suitable, accessible interventions, we must objectively consider the socio-ecological factors which influence participation in walking activities. For example, walking may be influenced by the volume and type of activities one's partner participates in (i.

View Article and Find Full Text PDF

Purpose: Appropriate opioid management is crucial to reduce opioid overdose risk for ICU surgical patients, which can lead to severe complications. Accurately predicting postoperative opioid needs and understanding the associated factors can effectively guide appropriate opioid use, significantly enhancing patient safety and recovery outcomes. Although machine learning models can accurately predict postoperative opioid needs, lacking interpretability hinders their adoption in clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!